1. Background
2. Objectives
3. Methods
3.1. Ethical Statement and Animals
3.2. Extraction and Chemical Analysis
3.3. Total Phenolic Quantification
3.4. Total Flavonoid Quantification
3.5. Experimental Design
| Groups | Purpose | Dosage (per kg) | Treatment | Description |
|---|---|---|---|---|
| 1 | Negative control | - | Water + Standard food | Healthy control |
| 2 | Positive disease model | 25 mg/kg | Methimazole only | Hypothyroid (stress control) |
| 3 | Assess extract alone | 1000 mg/kg | Walnut extract only | Walnut control |
| 4 | Assess therapeutic effect | 25 mg/kg + 1000 mg/kg | Methimazole + Walnut | Treated with walnut after stress induction |
| 5 | Compare with standard therapy | 25 mg/kg + 1.6 µg/kg | Methimazole + Levothyroxine | Standard drug treatment |
3.6. Serum Levels of Thyroid Hormones and Thyroid-Stimulating Hormone
3.7. Determination of Malondialdehyde Levels
3.8. Assessment of Catalase Activity
3.9. Assessment of Superoxide Dismutase Activity
3.10. Nitric Oxide Level Assessment
3.11. Statistical Analysis
4. Results
4.1. Chemical Composition of the Walnut Oil
| Chemical Categories (%) | Carbon Number | Content (%) | Reference Content (%) |
|---|---|---|---|
| Fatty acids 63.4 | |||
| Myristic acid | C14 | 1.0 | 0.02 - 1.9 (30, 31) |
| Palmitic acid or palmitate esters | C16 | 12.2 | 6.2 - 30.6 (27, 29, 30) |
| Linoleic acid | C18:2 | 21.2 | 57 - 64 (27, 30) |
| Oleic acid or ethyl oleate | C18:1 | 17.9 | 13 - 24 (27, 31) |
| Stearic acid or stearate esters | C18:0 | 9.1 | 2.7 - 31 (27, 30) |
| Alkanes 17.8 | 2 - 47 (32) | ||
| Hentriacontane | C31 | 0.4 | |
| Octacosane | C28 | 0.4 | |
| Heptacosane | C27 | 0.4 | |
| Hexacosane | C26 | 0.8 | |
| Pentacosane | C25 | 0.7 | |
| Tetracosane | C24 | 0.4 | |
| Tricosane | C23 | 0.7 | |
| Docosane | C22 | 0.7 | |
| Heneicosane | C21 | 0.7 | |
| Eicosane | C20 | 0.6 | |
| Nonadecane | C19 | 1.7 | |
| Octadecane | C18 | 0.7 | |
| Heptadecane | C17 | 1.2 | |
| Hexadecane | C16 | 1.5 | |
| Pentadecane | C15 | 2.7 | |
| Tetradecane | C14 | 2.3 | |
| Tridecane | C13 | 0.7 | |
| Dodecane | C12 | 1.2 | |
| Cinnamic acid derivatives | 0.5 - 2.5 | ||
| 2-Ethylhexyl trans-4- methoxycinnamate | C18 | 0.5 | |
| Hydrocinnamic acid | C9 | 4.3 | |
| Phenols 18.8 | 2 - 68 (32, 33) | ||
| 2,4-Di-tert-butylphenol | C14 | 8.3 | |
| 4-tert-Octylphenol | C14 | 2.4 |
4.2. Phenolic and Flavonoid Content
4.3. Thyroid Hormones
| Variables | Control | Control-Stress | Control-Walnut | Stress-Walnut | Stress-Levothyroxine |
|---|---|---|---|---|---|
| T4 (nmol/L) | 6.06 ± 0.40 | 5.6 ± 0.35 | 5.68 ± 0.41 | 6.12 ± 0.28 | 5.6 ± 0.48 |
| P-value | 0.002 | 0.004 | 0.633 | 0.717 | 0.005 |
| T3 (nmol/L) | 0.74 ± 0.11 | 0.48 ± 0.08 c | 0.48 ± 0.10 c | 0.44 ± 0.15 | 0.52 ± 0.13 |
| P-value | 0.001 | 0.004 | 0.004 | 0.925 | 0.925 |
| TSH (ng/mL) | 1.85 ± 0.69 | 2.66 ± 0.30 | 1.43 ± 0.30 | 1.71 ± 0.39 $$ | 1.21 ± 0.47 $$$ |
| P-value | 0.000 | 0.034 | 0.632 | 0.011 | 0.000 |
| Anti-TPO (IU/mL) | 30.26 ± 3.97 | 32.88 ± 1.91 | 29.88 ± 5.26 | 31.14 ± 4.11 | 24.38 ± 6.36 $ |
| P-value | 0.029 | 0.405 | 1.000 | 0.733 | 0.014 |
Abbreviations: T4, thyroxine; T3, triiodothyronine; TSH, thyroid-stimulating hormone; anti-TPO, thyroid peroxidase antibody.
a Values are expressed as mean ± SD.
b If the difference between the means is not statistically significant (P > 0.05), it is meaningless and no symbol is used.
c This sign indicates a comparison with the control group. The difference between the means of two treatments is significant at P < 0.05.
4.4. Assessment of Oxidant Status
| Variables | Control | Control-Stress | Control-Walnut | Stress-Walnut | Stress-Levothyroxine |
|---|---|---|---|---|---|
| MDA (µmol/L) | 2.93 ± 0.14 | 3.39 ± 0.35 | 2.46 ± 0.33 | 2.97 ± 0.31 | 2.46 ± 0.10 $$$ |
| P-value | 0.000 | 0.180 | 0.112 | 0.519 | 0.000 |
| NO (µmol/L) | 26.18 ± 3.32 | 30.46 ± 1.77 | 26.53 ± 1.15 | 25.25 ± 4.08 | 24.18 ± 3.3 |
| P-value | 0.014 | 0.132 | 0.997 | 0.028 | 0.012 |
Abbreviation: MDA, malondialdehyde.
a Values are expressed as mean ± SD.
b If the difference between the means is not statistically significant (P > 0.05), it is meaningless and no symbol is used.
4.5. Assessment of Antioxidant Status
| Variables | Control | Control-Stress | Control-Walnut | Stress-Walnut | Stress-Levothyroxine |
|---|---|---|---|---|---|
| SOD (U/mL) | 0.388 ± 0.008 | 0.37 ± 0.015 | 0.4 ± 0.01 | 0.374 ± 0.018 | 0.392 ± 0.019 |
| P-value | 0.407 | 0.673 | 0.948 | 0.999 | 0.453 |
| CAT (U/mg) | 108.77 ± 5.15 | 91.51 ± 8.39 b | 103.4 ± 6.38 | 93.19 ± 10.17 | 96.73 ± 8.10 |
| P-value | 0.014 | 0.040 | 1.000 | 0.987 | 0.487 |
Abbreviations: SOD, superoxide dismutase; CAT, catalase.
a Values are expressed as mean ± SD.
b A comparison with the control group. The difference between the means of two treatments is significant at P > 0.05..
4.6. Histopathological Analysis
| Variables | Inflammatory Cell Infiltration | Vacuolar Degeneration | Congestion |
|---|---|---|---|
| Control | - | - | - |
| Walnut extract | - | - | - |
| Methimazole | + | + | ++ |
| Methimazole + Walnut extract | - | + | + |
| Methimazole + Levothyroxine | - | - | ++ |
Thyroid tissue: A, control group showing normal thyroid tissue architecture; B, black walnut extract group showing normal histological appearance; C, methimazole group exhibiting vascular congestion (↑), vacuolar degeneration (→), and inflammatory cell infiltration (*); D, methimazole + black walnut extract group showing vascular congestion (↑) and vacuolar degeneration (→), with no inflammatory infiltration; E, methimazole + levothyroxine group showing vascular congestion (↑), with no other pathological findings (abbreviation: H&E, hematoxylin and eosin staining; magnification 40x).




